GlaxoSmithKline plc (LON: GSK) recently received a number of ratings updates from brokerages and research firms:

  • 8/9/2017 – GlaxoSmithKline plc had its price target lowered by analysts at Berenberg Bank from GBX 1,885 ($24.55) to GBX 1,835 ($23.90). They now have a “buy” rating on the stock.
  • 8/8/2017 – GlaxoSmithKline plc was given a new GBX 1,610 ($20.97) price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 8/8/2017 – GlaxoSmithKline plc was given a new GBX 1,900 ($24.74) price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “buy” rating on the stock.
  • 8/7/2017 – GlaxoSmithKline plc had its price target lowered by analysts at Deutsche Bank AG from GBX 1,720 ($22.40) to GBX 1,610 ($20.97). They now have a “hold” rating on the stock.
  • 8/1/2017 – GlaxoSmithKline plc was given a new GBX 1,600 ($20.84) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 7/28/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/27/2017 – GlaxoSmithKline plc had its “reduce” rating reaffirmed by analysts at Kepler Capital Markets. They now have a GBX 1,520 ($19.79) price target on the stock.
  • 7/27/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at Credit Suisse Group. They now have a GBX 1,775 ($23.11) price target on the stock.
  • 7/27/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,900 ($24.74) price target on the stock.
  • 7/27/2017 – GlaxoSmithKline plc was given a new GBX 1,700 ($22.14) price target on by analysts at Morgan Stanley. They now have a “neutral” rating on the stock.
  • 7/27/2017 – GlaxoSmithKline plc had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 1,550 ($20.18) price target on the stock.
  • 7/26/2017 – GlaxoSmithKline plc was given a new GBX 1,500 ($19.53) price target on by analysts at S&P Global. They now have a “sell” rating on the stock.
  • 7/26/2017 – GlaxoSmithKline plc had its price target raised by analysts at Bryan, Garnier & Co from GBX 1,750 ($22.79) to GBX 1,790 ($23.31). They now have a “buy” rating on the stock.
  • 7/26/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Berenberg Bank. They now have a GBX 1,885 ($24.55) price target on the stock.
  • 7/26/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Investec. They now have a GBX 1,800 ($23.44) price target on the stock.
  • 7/26/2017 – GlaxoSmithKline plc was given a new GBX 1,900 ($24.74) price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “buy” rating on the stock.
  • 7/26/2017 – GlaxoSmithKline plc was given a new GBX 1,600 ($20.84) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 7/25/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,720 ($22.40) price target on the stock.
  • 7/25/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a GBX 1,700 ($22.14) price target on the stock.
  • 7/24/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 7/21/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at Credit Suisse Group.
  • 7/20/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Bryan, Garnier & Co. They now have a GBX 1,750 ($22.79) price target on the stock.
  • 7/20/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/20/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a GBX 1,900 ($24.74) price target on the stock.
  • 7/19/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG.
  • 7/18/2017 – GlaxoSmithKline plc had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a GBX 1,700 ($22.14) price target on the stock.
  • 7/14/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 7/13/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a GBX 1,900 ($24.74) price target on the stock.
  • 7/13/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 1,750 ($22.79) price target on the stock.
  • 7/5/2017 – GlaxoSmithKline plc was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a GBX 1,700 ($22.14) price target on the stock.
  • 7/3/2017 – GlaxoSmithKline plc had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 1,550 ($20.18) price target on the stock.
  • 6/30/2017 – GlaxoSmithKline plc had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,720 ($22.40) price target on the stock.
  • 6/30/2017 – GlaxoSmithKline plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 1,750 ($22.79) price target on the stock.
  • 6/16/2017 – GlaxoSmithKline plc had its price target raised by analysts at Jefferies Group LLC from GBX 1,800 ($23.44) to GBX 1,900 ($24.74). They now have a “buy” rating on the stock.
  • 6/14/2017 – GlaxoSmithKline plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,900 ($24.74) price target on the stock.

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1468.00 on Friday. The firm’s market cap is GBX 71.76 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56. The stock’s 50 day moving average price is GBX 1,598.34 and its 200 day moving average price is GBX 1,623.98.

The company also recently announced a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be paid a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date is Thursday, August 10th.

In other GlaxoSmithKline plc news, insider Victoria Whyte sold 4,820 shares of the business’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($22.05), for a total transaction of £81,602.60 ($106,267.22). Also, insider Patrick Vallance bought 861 shares of the business’s stock in a transaction on Friday, July 14th. The shares were purchased at an average cost of GBX 1,618 ($21.07) per share, for a total transaction of £13,930.98 ($18,141.66). Over the last three months, insiders have acquired 3,151 shares of company stock worth $5,054,922.

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.